title: Reply to L. Moscetti.
authors.affiliation: Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.
authors.forename: Marco
authors.initials: M
authors.lastname: Colleoni
authors.affiliation: Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.
authors.forename: Kathryn P
authors.initials: KP
authors.lastname: Gray
authors.affiliation: Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Gelber
authors.affiliation: Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.
authors.forename: Meredith M
authors.initials: MM
authors.lastname: Regan
authors.affiliation: Marco Colleoni, International Breast Cancer Study Group, Bern, Switzerland; and European Institute of Oncology, Milan, Italy; Kathryn P. Gray, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard T. H. Chen School of Public Health, Boston, MA; Richard D. Gelber, International Breast Cancer Study Group, Bern, Switzerland; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School; and Frontier Science and Technology Research Foundation, Boston, MA; Meredith M. Regan, International Breast Cancer Study Group, Bern, Switzerland; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Aron Goldhirsch, Breast Cancer, European Institute of Oncology, Milan, Italy; and International Breast Cancer Study Group, Bern, Switzerland.
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch